Clinical trials: Prostatic Biopsy
Neoplasms of the Prostate
An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue
To determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser irradiation.
- Trial name
- NCT04240639
- Testing
- AuroShell particle infusion
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Nanospectra Biosciences, Inc.
Breast Cancer, Prostate Cancer
Evaluation Protocols for Isolation of Analytes From Urine for Future Oncology Applications
The aim of this study is to evaluate and optimize protocols for the isolation and analysis of analytes in urine (cell-free nucleic acids, extracellular vesicles and proteins).
- Conditions
- Breast Cancer, Prostate Cancer, Urine, Liquid Biopsy
- Trial name
- URODETECT-WP1 (NCT05453604)
- Testing
- Colli-Pee UAS devices
- Where
- Belgium
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Novosanis NV
Prostate Cancer
Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
This registry is intended to measure the impact of Prolaris® testing on therapeutic decisions when added to standard clinical-pathological parameters in men with newly diagnosed prostate cancer.
- Trial name
- PROCEDE-2000 (NCT02209584)
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Prostate Cancer
ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting
The study is designed to confirm the performance of the ExoDx Prostate test in prior negative biopsy patients now presenting for a repeat prostate biopsy.
- Trial name
- NCT04357717
- Testing
- ExoDx Prostate
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Urologic Cancer
Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy
The study described here is being conducted to prospectively confirm the performance of the ExoDx Prostate gene expression assay in patients presenting for an initial prostate biopsy and support of CE-marking the test for a…
- Trial name
- NCT04720599
- Testing
- ExoDx Prostate(IntelliScore)
- Where
- 3 sites in United States, Germany
- Volunteers
- 120 people
- Sponsor
- Exosome Diagnostics, Inc.
Prostate Cancer
Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason Score of ≤ 3+4 severity who are candidates for active…
- Trial name
- proSPECT-AS (NCT02615067)
- Testing
- 99mTc-MIP-1404 Injection, Whole-Body Planar and pelvic SPECT/CT scan
- Where
- 45 sites in United States, Canada
- Volunteers
- 531 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostate Cancer
Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients
This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.
- Trial name
- NCT01954004
- Where
- United States
- Volunteers
- 1,270 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Cancer of Prostate
Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
The purpose of this research study is investigate a new and validated urine test which predicts the likelihood of high grade prostate cancer on an initial prostate biopsy The current protocol has two objectives; one is to further…
- Trial name
- NCT03031418
- Testing
- ExoDx Prostate Intelliscore
- Where
- 18 sites in United States
- Volunteers
- 532 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Prostate Cancer
A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy
he most common method for performing a prostate biopsy procedure is the ultrasound guided transrectal procedure. The information obtained from the standard prostate biopsy is deficient and even misleading.
- Trial name
- NaSBxP01 (NCT01480375)
- Testing
- Smartbx™ system.
- Where
- Israel
- Volunteers
- 524 people
- Sponsor
- UC Care, Ltd.
Prostate Cancer
Registry to Measure the Impact of Adding Genomic Testing
This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
- Trial name
- NCT02454595
- Testing
- Registry
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
PCA, Prostate Cancer
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection…
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
- Trial name
- BiPASS (NCT07052214)
- Testing
- 68Ga-PSMA-11
- Where
- 18 sites in United States, Australia
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostatic Neoplasms, Locally Advanced
Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer
The purpose of this study is to compare the efficacy and safety of combined radiotherapy and hormone therapy and hormone therapy alone in the treatment of clinically locally advanced prostate cancer (T3-T4 or pT3 on biopsy, N0…
- Trial name
- NCT01122121
- Testing
- Leuprorelin SR, Radiotherapy, Flutamide
- Where
- France
- Volunteers
- 273 people
- Sponsor
- Takeda
Immunity, Innate, Prostatic Neoplasm
Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy
This study will look at measuring the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in subjects being screened for prostate cancer using prostate biopsy.
- Trial name
- ANKA-PCA (NCT03242265)
- Testing
- IVDD for NK cell activity in whole blood
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- ATGen Canada Inc
Prostatic Neoplasms
Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels
This is a multi-centre prospective study in which blood samples will be taken from 1500 male patients aged between 21-80 scheduled for prostate biopsy.
- Trial name
- NCT02771769
- Testing
- blood draw
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Chronix Biomedical Corporation
Prostate Cancers
PRostate Cancer Enhanced Diagnosis by Calibration Technology
The CARE® Phantom system is a medical device system that is being developed has been designed to enable the quantitative measurement of the apparent diffusion coefficient (ADC) in the prostate of patients undergoing a…
- Trial name
- PREDICT (NCT06607783)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 66 people
- Sponsor
- Gold Standard Phantoms